Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$0.93
▲ $0.02 (+2.3%)
Market data updated: 09/25 08:31 PM
Fundamentals updated: 09/24/2026
News analyzed: 09/25/2026
Market Cap
Not available
Day Range
$0.90 - $0.95
52-Week Range
$0.53 - $3.07
Beta
—
Next Earnings
04.11.2026
Support
$0.53
Resistance
$1.05
IVVD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-25.1% (1Y)
Strengths: 15/28 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 110.5%
Growth
Biggest negative driver
Operating margin
Operating margin: -104.0% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
58
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $0.91
Evidence: Narrative Gap moved from -24 to 7 day-over-day
What happened after
Still awaiting outcome
today · $0.91
Evidence: FOMO score jumped from 3 to 40 day-over-day
What happened after
Still awaiting outcome
20d ago · $0.83
Evidence: Narrative Gap moved from 6 to -29 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
55
Momentum
67
Risk
40
Sentiment
68
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Invivyd, Inc. has centered on leadership changes and upcoming clinical milestones. In September 2026, the company announced that Marc W. Elia, its Chairman, was appointed as CEO, while also highlighting progress in its VYD2311 program, with top-line data from the DECLARATION and LIBERTY studies expected by the end of Q3 2026. Additionally, Invivyd disclosed inducement grants to new hires under Nasdaq listing rules and its participation in investor conferences.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Invivyd, Inc.. News trend score: 68. Reason: 8 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
35
🎯 Conviction (vs. Emotion)
57
Psychology
40
Fundamentals
30
Technical
67
Valuation
55
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+2%
Market Narrative
64
Fundamental Reality
57
Narrative Gap
+7
🧠 StockIQ Psychologist
The market behavior for IVVD suggests a dominant psychological state of panic selling, driven by weak momentum, elevated volume, and heightened volatility. The narrative gap (-29) further implies a disconnect between market sentiment and underlying fundamentals, consistent with distressed selling. The key open question is whether the selling pressure will persist or if a rebound could emerge as traders reassess the stock’s valuation relative to its fundamentals. The absence of herd behavior or euphoria reinforces the idea of a fragmented, cautious market stance.
Updated: 09/09/2026, 05:15 AM
What could change this?
👥 What the crowd believes
"Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy"
"DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks"
"Cantor Fitzgerald reiterates Invivyd (NASDAQ:IVVD) with a Overweight and maintains $10 price target"
🧠 Market Brain events driving this
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Thorstein Veblen — 21/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect deep methodological contrasts. Benjamin Graham and his Enterprising Investor variant overwhelmingly endorse it as a bargain, with near-perfect scores, while Walter Bagehot and Charles Mackay see it as resilient and free from speculative frenzy. Meanwhile, growth-oriented investors like Peter Lynch and Philip Fisher—despite Fisher’s lower score—still see potential, though Fisher’s stricter quality bar dampens enthusiasm. Mid-tier methodologies like Howard Marks and Samuel Nelson view it as cautiously favorable, balancing risk and cycle positioning, though their scores dip below the Graham camp’s enthusiasm. On the other end, efficiency skeptics (Malkiel/Bogle, Housel) and contrarian trend-followers (Livermore, Veblen) dismiss it outright, with Livermore’s low score suggesting a clear technical misalignment. The divide underscores whether the stock’s value or growth merits outweigh its perceived risks or market inefficiencies.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 94
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 77
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 62
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 60
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 45
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 44
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 41
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 38
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 286 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 2 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-104.0%
Net Margin
-98.2%
EBITDA Margin
-104.0%
ROE
-21.7%
ROA
-19.0%
ROIC
—
EPS
-$0.30
Cash
$226.69M
Total Debt
—
Current Ratio
7.24
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$0.93
Estimated Fair Value (DCF)
-$8.64
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-72.86M | $-66.85M |
| 2 | 19.4% | $-86.98M | $-73.21M |
| 3 | 13.8% | $-98.94M | $-76.40M |
| 4 | 8.1% | $-106.98M | $-75.79M |
| 5 | 2.5% | $-109.65M | $-71.27M |
Base FCF (last actual year)
$-58.29M
Terminal Value
$-1.73B
Present Value of Terminal Value
$-1.12B
Enterprise Value
$-1.49B
Net Debt
$0
Equity Value
$-1.49B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.40
Tangible Book Value per Share (Tangible NAV)
$1.40
Sentiment based on basic keywords (not AI) — 8 positive, 7 neutral, 5 negative out of the last 20 articles.
Benzinga · 21.9.2026
Benzinga · 21.9.2026
Benzinga · 14.9.2026
MarketBeat · 13.9.2026
Yahoo · 13.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
ChartMill · 1.9.2026
MT Newswires · 1.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Benzinga · 1.9.2026
Benzinga · 1.9.2026
Benzinga · 1.9.2026
Benzinga · 27.8.2026
Zacks · 13.8.2026
GlobeNewswire · 13.8.2026
Zacks · 12.8.2026
Invivyd, Inc. (IVVD) currently has a StockIQ AI score of 58/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
IVVD currently scores 58/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
IVVD's technical score is 67/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 110.5%; Earnings per share (EPS) growth: 79.0%; Free cash flow growth: 65.8%.
Based on the real signals StockIQ computed: Operating margin: -104.0% (negative); Net margin: -98.2% (negative); ATR: 9.8% of price.
StockIQ has no recorded dividend payment history for IVVD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 10 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Sheffield Ian | Grant/Award from Employer | 31.8.2026 | 100,000 | +100,000 | — |
| Elia Marc | Grant/Award from Employer | 30.8.2026 | 10,700,000 | +10,700,000 | — |
| Allen Robert D. III | Open Market Sale | 18.8.2026 | 17,043 | -17,043 | $0.84 |
| Lee Timothy Edward | Open Market Sale | 18.8.2026 | 18,425 | -18,425 | $0.84 |
| Duke William E. | Open Market Sale | 18.8.2026 | 18,425 | -18,425 | $0.84 |
| Green Julie | Open Market Sale | 18.8.2026 | 18,425 | -18,425 | $0.84 |
| Andersen Jill | Open Market Sale | 18.8.2026 | 30,706 | -30,706 | $0.84 |
| Green Julie | Open Market Sale | 17.8.2026 | 22,355 | -22,355 | $0.72 |
| Andersen Jill | Open Market Sale | 17.8.2026 | 37,256 | -37,256 | $0.72 |
| Allen Robert D. III | Open Market Sale | 17.8.2026 | 20,679 | -20,679 | $0.72 |
| Lee Timothy Edward | Open Market Sale | 17.8.2026 | 22,355 | -22,355 | $0.72 |
| Duke William E. | Open Market Sale | 17.8.2026 | 22,355 | -22,355 | $0.72 |
| Duke William E. | Exercise of Derivative Securities | 15.8.2026 | 102,000 | -102,000 | — |
| Duke William E. | Exercise of Derivative Securities | 15.8.2026 | 102,000 | +102,000 | — |
| Andersen Jill | Exercise of Derivative Securities | 15.8.2026 | 170,000 | +170,000 | — |
| Green Julie | Exercise of Derivative Securities | 15.8.2026 | 102,000 | +102,000 | — |
| Lee Timothy Edward | Exercise of Derivative Securities | 15.8.2026 | 102,000 | -102,000 | — |
| Allen Robert D. III | Exercise of Derivative Securities | 15.8.2026 | 102,000 | +102,000 | — |
| Allen Robert D. III | Exercise of Derivative Securities | 15.8.2026 | 102,000 | -102,000 | — |
| Lee Timothy Edward | Exercise of Derivative Securities | 15.8.2026 | 102,000 | +102,000 | — |
| Andersen Jill | Exercise of Derivative Securities | 15.8.2026 | 170,000 | -170,000 | — |
| Green Julie | Exercise of Derivative Securities | 15.8.2026 | 102,000 | -102,000 | — |
| Mina Michael | Grant/Award from Employer | 31.7.2026 | 1,125,000 | +1,125,000 | — |
| Mina Michael | Grant/Award from Employer | 31.7.2026 | 1,125,000 | +1,125,000 | — |
| BOLNO PAUL | Grant/Award from Employer | 19.5.2026 | 32,876 | +32,876 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
30,556,394 shares short as of 2026-09-15 · vs. 29,787,846 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.8% of trading volume this week was short selling, vs. 66.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology